May drugs be a cost-effective investment in Spanish health system?

Medicina Clinica

Volumn 117, Issue 16, 2001, Pages 622-624

  Soto, J ^a   Olivella, P ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; HUMAN; PRESCRIPTION; SPAIN; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; PHARMACOECONOMICS; PUBLIC HEALTH;

COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; NATIONAL HEALTH PROGRAMS; SPAIN;

EID: 0035904742     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72199-9     Document Type: Article

References (34)

1. La industria farmacéutica en cifras
2. La sanidad en España: La dificultad de todo para todos y gratis
3. Los límites de la capacidad de financiación sanitaria y alternativas
4. La regulación de los medicamentos: Teoría y práctica
5. Pharmaceutical expenditure in Spain: Cost and control
6. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone
7. Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in the prevalence of asthma
8. Treatment of hypogammaglobulinaemia with intravenous immunoglobin, 1973-1993
9. A retrospective assessment of cost avoidance associated with the use of nadacromil sodium metered-dose inhaler in the treatment of patients with asthma
10. Hospital admission for asthma in east London: Association with characteristics of local general practices, prescribing, and population
11. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD
12. Outcome analysis and cost assessment in immunologic disorders
13. Expanding Medicaid drug formulary coverage. Effects on utilization of related services
14. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost and equity
15. On squeezing ballooms: Cost control fails again
16. Limited lists of drugs: Lessons from abroad
17. Impact of a nationwide limited prescribing list: Preliminary findings
18. Effects on Medicaid drug-payment limits on admission to hospitals and nursing homes
19. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophremie
20. Intended and unintended consequences of HMO cost-containment strategies: Results from the Managed Care Outcomes Project
21. Unintended effects of a cost-containment policy: Results of a natural experiment in Germany
22. Is there a link between pharmaceutical consumption and improved health in OECD countries?
23. The health and economic benefits of influenza vaccination for healthy and at-risk persons age 65 to 74 years
24. An economic cost analysis of oral gancivlovir prophylaxis in the prevention of CMV disease
25. Economic impact od standardized orders for antimicrobial prophylaxis program
26. Treatment of multiple sclerosis with interferon beta: An appraisal of cost-effectiveness and quality of life
27. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine
28. Farmacoeconomía: El cálculo de la eficiencia
29. Evaluación económica de medicamentos: Aplicaciones prácticas para los diferentes agentes decisores
30. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions
31. Medicina basada en la eficiencia: Una inevitable realidad para el siglo xxi
32. An integrated national pharmaceutical policy for the United Kingdom?
33. Drug cost containment policies in Italy: Are they really effective in the long-run? The case of minimum reference price
34. Adverse events associated with prescription drug cost-sharing among poor and elderly persons